Skip to main content

Trastuzumab (International)

In the US, Trastuzumab (trastuzumab systemic) is a member of the drug class HER2 inhibitors and is used to treat Breast Cancer, Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Esophageal Carcinoma, Gastric Cancer and Salivary Gland Cancer.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Categories

Antineoplastic agent

Biological response modifier, BRM


Anti-HER2 monoclonal antibody

Chemical Name

Immunoglobulin G1 (human-mouse monoclonal rhuMab HER2γ₁-chain antihuman p185c-erbB²receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer (WHO )

Foreign Names

Generic Names

Brand Names


BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.